CA2368215A1 - Compositions et procedes pour le traitement de diabetes - Google Patents

Compositions et procedes pour le traitement de diabetes Download PDF

Info

Publication number
CA2368215A1
CA2368215A1 CA002368215A CA2368215A CA2368215A1 CA 2368215 A1 CA2368215 A1 CA 2368215A1 CA 002368215 A CA002368215 A CA 002368215A CA 2368215 A CA2368215 A CA 2368215A CA 2368215 A1 CA2368215 A1 CA 2368215A1
Authority
CA
Canada
Prior art keywords
insulin
diabetes
cells
luteolin
brickellia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002368215A
Other languages
English (en)
Inventor
Randy H. Ziegler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2368215A1 publication Critical patent/CA2368215A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)

Abstract

L'invention concerne des produits extraits de Brickellia californica et des flavonoïdes isolés, dont l'apigénine, la lutéoline, la quercétine et dihydroxykaemférol, purifiés provenant de Brickellia californica, qui sont utiles pour le traitement de diabètes. Les produits extraits et des flavonoïdes peuvent être utilisés en alternance dans le traitement des diabètes insulinodépendant et non insulinodépendant car ces substances entraînent la baisse sensible du glucose.
CA002368215A 1999-04-05 2000-04-04 Compositions et procedes pour le traitement de diabetes Abandoned CA2368215A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12782499P 1999-04-05 1999-04-05
US60/127,824 1999-04-05
PCT/US2000/008957 WO2000059522A1 (fr) 1999-04-05 2000-04-04 Compositions et procedes pour le traitement de diabetes

Publications (1)

Publication Number Publication Date
CA2368215A1 true CA2368215A1 (fr) 2000-10-12

Family

ID=22432145

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002368215A Abandoned CA2368215A1 (fr) 1999-04-05 2000-04-04 Compositions et procedes pour le traitement de diabetes

Country Status (7)

Country Link
EP (1) EP1169047A1 (fr)
JP (1) JP2002541116A (fr)
AU (1) AU780233B2 (fr)
BR (1) BR0009592A (fr)
CA (1) CA2368215A1 (fr)
MX (1) MXPA01010037A (fr)
WO (1) WO2000059522A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020068704A1 (en) * 1999-04-05 2002-06-06 Ziegler Randy H. Compositions and methods for treatment of diabetes
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
NZ526041A (en) * 2000-12-21 2005-01-28 The Quigley Corp Method and composition for the treatment of diabetic neuropathy
KR20040048407A (ko) * 2001-09-06 2004-06-09 시녹스, 인크. 3-데옥시플라보노이드에 의한 ｔ-림프구 활성화의 억제 및그의 관련 치료법
AU2003225244A1 (en) 2002-05-06 2003-11-11 Diakron Pharmaceuticals, Inc. Pharmaceutical compositions for lowering blood glucose and blood cholesterol levels
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
EP1708689A2 (fr) * 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions pour traiter ou prevenir l'obesite et les troubles de resistance a l'insuline
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2006138418A2 (fr) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Amelioration de la performance cognitive avec des activateurs de sirtuine
JP2008007452A (ja) * 2006-06-28 2008-01-17 Ajinomoto Co Inc 膵β細胞保護剤
US8287677B2 (en) 2008-01-31 2012-10-16 Kimberly-Clark Worldwide, Inc. Printable elastic composite
JP5594719B2 (ja) * 2010-01-06 2014-09-24 国立大学法人神戸大学 筋肉の糖取り込み促進剤

Also Published As

Publication number Publication date
MXPA01010037A (es) 2003-07-14
JP2002541116A (ja) 2002-12-03
EP1169047A1 (fr) 2002-01-09
AU4196400A (en) 2000-10-23
AU780233B2 (en) 2005-03-10
WO2000059522A1 (fr) 2000-10-12
BR0009592A (pt) 2002-01-08

Similar Documents

Publication Publication Date Title
Rajagopal et al. Antihyperglycaemic and antihyperlipidaemic effects of Nymphaea stellata in alloxan-induced diabetic rats
Jabri et al. Role of laxative and antioxidant properties of Malva sylvestris leaves in constipation treatment
Singh et al. Suppl 2: Medicinal chemistry of the anti-diabetic effects of Momordica charantia: active constituents and modes of actions
AU780233B2 (en) Compositions and methods for treatment of diabetes
Knoll Satietin: A highly potent anorexogenic substance in human serum
US20020068704A1 (en) Compositions and methods for treatment of diabetes
KR100509438B1 (ko) 경구적으로 활성인 여주의 분획, 이것의 활성 펩티드 및 당뇨병 치료에 있어서 이들의 사용
US6416794B1 (en) Methods and compositions for treating cataracts using substances derived from yeast or saltbush
JP2005500263A (ja) 糖尿病の予防及び治療を目的とする医薬草本化合物
Ingle The functional interrelationship of the anterior pituitary and the adrenal cortex
Binita et al. The therapeutic potential of Syzygium cumini seeds in diabetes mellitus
GILLIES et al. Corticotrophin releasing activity in extracts of the stalk median eminence of Brattleboro rats
Mahood Effects of Pimpinella anisum oil extract on some biochemical parameters in mice experimentally induced for human polycystic ovary syndrome
Owyang Endocrine changes in pancreatic insufficiency
Yokoyama Hypothalamic and hormonal control of the photoperiodically induced vernal functions in the White-crowned Sparrow, Zonotrichia leucophrys gambelii: 1. The effects of hypothalamic lesions and exogenous hormones
Hastings et al. Melatonin and the brain in photoperiodic mammals
US20030165581A1 (en) Compositions for treating diabetes mellitus, methods of use and manufacturing process of the same
Bilchik et al. Amelioration of cholinergic-induced pancreatitis with a selective cholecystokinin receptor antagonist
US20090053332A1 (en) Compositions for diabetes treatment and prophylaxis
US8865237B2 (en) Method of preparing dialysed extract of fenugreek seeds which induces hypoglycemia, mediated, in part, via stimulation of insulin signaling pathway
Umamaheswari et al. Effect of the fractions of Coccinia grandis on naphthalene-induced cataractogenesis in rats
CN101884767A (zh) 防治糖尿病并发症及衰老的植物提取物组合物及制备方法
Anwar et al. The effect of n-butanol fraction of gaharu (Aquilaria microcarpa Baill.) leaves on blood glucose and liver glycogen levels in alloxan-induced male rats
Da Costa Mousinho In vitro assessment of the anti-diabetic activity of Sclerocarya birrea and Ziziphus mucronata
Nargund Investigation of Diospyros Malabarica Kostel. and Melia Azedarach Linn. and Their Secondary Metabolites in the Management of Diabetes Mellitus and Its Complications in Streptozotocin-Induced Diabetic Rats

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead